Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: bit.ly/4BvJVrG

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

See you soon at @myESMO

DeLLphi-304: 🫁 Tarlatamab sustained its OS benefit at 23-month follow-up, improving median OS to 13.6 vs 8.4 months (HR 0.62) @OncoAlert #ESMO26 @ESMO_Open #ESMOAmbassadors #LungCancer #ESMOcommunity @myESMO

Compelling data for WGS ctDNA de-escalation strategies in HER2+ MBC #ESMO26 @OncoAlert

🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1) ➡️two cohorts n=60 #PDAC ➡️safety- mainly haem, none precluded surgery ➡️ORR 63% & 87%;MPR in 17% ➡️R0 resection rate 100% ✅6 mth EFS rate 87% & 96% ➡️100% ⬇️CA19.9; OS pending @myESMO #ESMO26 @OncoAlert

Tucatinib added to HP is a nice option for 1L low volume brain only disease after local therapy. Particularly in patients with no extracranial disease where the toxicity of ADC is not desired. #ESMO26

Why does T-DXd stop working? Paired biopsies before and after ADCs, presented by @PTarantinoMD at ESMO 2026, give a clear first answer: the tumor rarely loses HER2. Instead, several mechanisms coexist in the same tumor:
Drug pumps up: ABCB1 rose in 5 of 7 T-DXd-treated tumors, ABCC1 in 4 of 7.
Uptake down: MAN2A2, a glycosylation enzyme, fell in 5 of 7. In cell models, silencing it reduced T-DXd binding and internalization.
After sacituzumab, no recurrent pattern at all. For clinic: a repeat biopsy that only re-checks HER2 will usually come back "still positive" and explain nothing. The resistance happens after the drug reaches the cell. Seven patients, hypothesis-generating. But it tells us what the next biopsy should measure. #bcsm #ESMO26 @myESMO

Day 2 #ESMO26 Highlights: 1. CheckMate8HW: Nivo+Ipi in mCRC Breast Ca 2. postMONARCH: Abema+Fulv HR+ 3. VIKTORIA-1: Gedatolisib HR+ 4. TROPION-Breast02: DatoDXd TNBC GU/Gyn 5. PROTEUS: Periop Apa+ADT in Prostate Cancer #OncTwitter #bcsm #gusm #gism @myESMO 1/10

RT @KatsuakiMaehara: 🫁🫁 DeLLphi-305 🫁🫁 💥 This is a hypothesis and falls within the realm of speculation. 💥I am specifically treating the…

It was a great honour to present the results of the phase 3 INTerpath-001 clinical trial at the #ESMO26 Congress in Madrid. This international trial included 1137 patients, across 157 sites, whose melanoma had been surgically removed, but who were at very high risk of it returning. The trial showed adding #intismeran autogene, an mRNA based individualised neoantigen therapy, to pembrolizumab reduced the risk of recurrence or death by 42%. This is the first phase 3 study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumour can reduce the risk of recurrence or death from cancer. That fingerprint is read by sequencing the tumour, then a ‘wanted poster’ of the cancer is made as mRNA, showing the immune system exactly what to look for and attack. Having succeeded in melanoma, this proof of concept could mark the beginning of a foundational shift in how we treat cancer. Read more >melanoma.org.au/news/persona… A huge thank you to all patients and teams involved. @myESMO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear

OptiTROP-Lung06: Sac-TMT + pembro vs chemo + pembro in NSQ NSCLC. PFS correlation (?) with TROP2 expression from the concomitant @NEJM publication (in the appendix). #ESMO26

#ESMO26 Dr. Caicun Zhou presents OptiTROP-Lung06: 1L Sac-TMT (TROP2 ADC) + pembro vs chemo + pembro in non-squamous NSCLC. PFS 15m vs 5.7m (HR 0.49). OS immature but 1y rate 78% vs 66% (HR 0.58). mDOR 13.6m vs 6.8m. TEAEs leading to d/c of drug 6% with Sac-TMT 14% with chemoIO.

Science takes centre stage once again as Presidential Symposium II welcomes a packed auditorium at #ESMO26. ✨

HARMONI-Gi comparing Ivonescimib plus chemo vs Durvalumab plus chemo in 1L advance BTC, Ivonescimib significantly improves PFS and OS over Durvalumab. #ESMO2026 @myESMO @curijoey @OncoAlert

In patients harbouring MET mutation mNSCLC progressing on Osimertinib, the addition of savolitinib improves PFS and OS compared to the SoC. #ESMO26 @myESMO @curijoey @StephenVLiu @OncoAlert @darioT_

KRASCENDO trial: Divarasib a second generation KRAS G12C inhibitor improves PFS and OS in mNSCLC compared to 1st Generation sotorasib. #ESMO2026 @curijoey @myESMO @darioT_ @OncBrothers

In DeLLphi-305: The combination of Tarlatamab+ Durvalumab improves both OS (21 vs 12 months HR 0.42) and PFS in ES-SCLC. This is remarkable in such a lethal disease with high recurrence rates and mortality. #ESMO2026 #ESMOAmbassadors @myESMO @StephenVLiu @tompowles1 @FAndreMD

VOLGA trial : The Arm1 - in MIBC, neoadjuvant Durvalumab + EV followed by surgery then adjuvant Durvalumab showed better EFS (NR vs 12 months HR 0.51) and OS (NR in both arms, HR 0.58) compared to the standard of care. #ESMO2026 @DrChoueiri @myESMO @darioT_ @E_de_Azambuja

In INTerpath-001, the combination of adjuvant Intismeran plus pembro is superior to pembro alone in resected melanoma mproves RFS in ITT 70% vs 82.2% HR 0.58 #ESMO2026 @darioT_ @myESMO @DrChoueiri @FAndreMD @OncoAlert